The ENVISION trial reported an 82.3% duration of response at 12 months for UGN-102. Could you explain the clinical implications of this result for patients with LG-IR-NMIBC?

How does the efficacy of UGN-102 compare to existing surgical treatments for LG-IR-NMIBC, and what advantages does a non-surgical approach offer to patients?

Considering the non-surgical nature of UGN-102, what impact do you anticipate this treatment will have on the quality of life and overall experience of patients undergoing treatment for LG-IR-NMIBC?

UGN-102 utilizes mitomycin delivered via UroGen’s RTGel® technology. Can you discuss how this formulation and delivery method enhance its effectiveness and safety profile in treating LG-IR-NMIBC?

The ENVISION trial findings indicated a favorable safety profile for UGN-102. What are the most notable aspects of its safety, and how do these compare to the risks associated with surgical treatments?

With an 82.3% duration of response at 12 months, what are the expected long-term outcomes for patients treated with UGN-102, and how might this influence future treatment protocols for LG-IR-NMIBC?

What are the next steps for UGN-102 in terms of regulatory approval, and how might this potential FDA approval change the landscape of treatment for LG-IR-NMIBC?

Beyond LG-IR-NMIBC, are there other urological or oncological conditions where UGN-102 or similar non-surgical treatments might show promise? What are UroGen Pharma Ltd.'s plans for exploring these potential applications?